Brett Kaplan - Aug 26, 2024 Form 4 Insider Report for Eliem Therapeutics, Inc. (ELYM)

Role
Chief Operating Officer
Signature
/s/ Emily Pimblett, as Attorney-in-Fact
Stock symbol
ELYM
Transactions as of
Aug 26, 2024
Transactions value $
$0
Form type
4
Date filed
8/26/2024, 05:47 PM
Previous filing
Feb 23, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Stock Option (Right to Buy) Award $0 +465K $0.00 465K Aug 26, 2024 Common Stock 465K $5.95 Direct F1
transaction ELYM Restricted Stock Units Award $0 +77.5K $0.00 77.5K Aug 26, 2024 Common Stock 77.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on August 26, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through August 26, 2028, subject to the Reporting Person's continued service.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
F3 The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.